Neurocrine Biosciences Schedules Q3 Financial Results Call
Upcoming Conference Call and Webcast Set for October 28
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is gearing up to share its financial performance for the third quarter. The eagerly anticipated conference call and accompanying webcast will take place at 1:30 p.m. Pacific Time, or 4:30 p.m. Eastern Time, on October 28.
The timeline for the event includes significant announcements as follows:
- Q3 2025 Press Release: Scheduled for 1:00 p.m. PT / 4:00 p.m. ET on October 28
- Q3 2025 Conference Call: Conducted at 1:30 p.m. PT / 4:30 p.m. ET on the same day
- Domestic Dial-In Number: 800-274-8461
- International Dial-In Number: 203-518-9814
- Conference ID: NBIX
Participants can access the webcast through Neurocrine Biosciences' official website under the Investors section. Following the live event, a recorded broadcast will be available for one month, ensuring that those unable to attend can still engage with the insights shared.
About Neurocrine Biosciences
Neurocrine Biosciences is at the forefront of creating breakthrough treatments in the field of neuroscience. Their mission revolves around alleviating suffering for individuals with significant unmet medical needs. The company focuses on developing innovative therapies for a variety of challenging conditions including neurological, neuroendocrine, and neuropsychiatric disorders.
The portfolio showcases FDA-approved medications targeting conditions such as tardive dyskinesia and chorea linked to Huntington's disease, along with treatments for classic congenital adrenal hyperplasia and endometriosis. With a promising pipeline that includes several candidates in crucial clinical stages, Neurocrine's dedication to addressing complex diseases and disorders is evident.
For three decades, Neurocrine has leveraged deep insights into the intricate relationships between brain function and bodily systems, pursuing advanced medical solutions. They remain relentless in their quest to manage and mitigate the impact of debilitating health issues, embodying the principle that patients deserve courageous scientific innovation.
To learn more about their endeavors and progress, interested parties can visit their website or follow Neurocrine on various social media platforms including LinkedIn, X, and Facebook.
Trademark mentions such as NEUROCRINE and YOU DESERVE BRAVE SCIENCE reflect the company's commitment to its brand and mission to contribute meaningfully to healthcare.
Frequently Asked Questions
What is the purpose of Neurocrine's upcoming conference call?
The conference call is intended to announce and discuss the financial results for the third quarter of 2025.
When will the Q3 financial results be released?
The financial results will be released on October 28, 2025, at 1:00 p.m. PT.
How can I access the conference call?
Individuals can join the conference call by dialing the specified numbers provided by Neurocrine Biosciences.
Where can I find more information about Neurocrine Biosciences?
More details about the company and its initiatives can be found on their official website.
What therapeutic areas does Neurocrine focus on?
Neurocrine focuses primarily on treating neurological, neuroendocrine, and neuropsychiatric disorders.
